The Efficacy and Safety of CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma: a Randomized, Double-blind, Double Dummy, Multicenter Study

Trial Profile

The Efficacy and Safety of CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma: a Randomized, Double-blind, Double Dummy, Multicenter Study

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Vorolanib (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms CONCEPT
  • Sponsors AnewPharma
  • Most Recent Events

    • 05 Jun 2018 According to the results presented at the 54th Annual Meeting of the American Society of Clinical Oncology, a total of 101 patients have been randomized currently.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 09 Nov 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top